查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1982804

全球呼吸系統疾病疫苗市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Respiratory Disease Vaccine Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 166 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計呼吸道疾病疫苗市場將從 2025 年的 760.1 億美元成長到 2034 年的 1,128.5 億美元，2026 年至 2034 年的複合年成長率為 4.49%。

隨著醫療衛生系統將重點放在預防呼吸道感染疾病上，全球呼吸道疾病疫苗市場正顯著成長。針對流感、肺炎和其他呼吸道感染疾病的疫苗在保護公眾健康方面發揮著至關重要的作用。免疫接種計劃的擴大和疾病預防意識的提高正在推動市場成長。

多種因素正在推動呼吸道疾病疫苗市場的成長。呼吸道感染疾病病例的增加以及政府對免疫規劃投入的加大，都提振了疫苗需求。此外，疫苗研發和生物技術的進步，也促使人們開發出更有效、保護更廣泛的疫苗。

隨著醫療機構將疾病預防策略置於優先地位，呼吸道疾病疫苗市場預計將持續擴張。疫苗技術的進步，包括配方和給藥系統的改進，有望提高免疫接種的有效性。此外，全球疫苗接種工作的推進和醫療服務可近性的提高預計將支持市場的長期發展。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球呼吸系統疾病疫苗市場：依技術分類

  • 市場分析、洞察與預測
  • 病毒載體
  • mRNA
  • 組合型
  • 衰減
  • 失活
  • 重組
  • 其他技術

第5章 全球呼吸系統疾病疫苗市場：依年齡層別分類

  • 市場分析、洞察與預測
  • 兒童
  • 成人

第6章 全球呼吸系統疾病疫苗市場：依感染疾病

  • 市場分析、洞察與預測
  • 冠狀病毒感染疾病（COVID-19）
  • 流感
  • 呼吸道融合細胞病毒（RSV）
  • 肺炎
  • 其他感染疾病

第7章 全球呼吸系統疾病疫苗市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 其他分銷管道

第8章 全球呼吸道疾病疫苗市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AstraZeneca
    • Emergent BioSolutions Inc
    • GSK Plc
    • Johnson & Johnson Services Inc
    • Merck & Co. Inc
    • Novavax
    • Pfizer Inc
    • Sanofi SA
    • Serum Institute Of India Pvt. Ltd
    • Sinovac
簡介目錄
Product Code: VMR11212585

The Respiratory Disease Vaccine Market size is expected to reach USD 112.85 Billion in 2034 from USD 76.01 Billion (2025) growing at a CAGR of 4.49% during 2026-2034.

The global respiratory disease vaccine market has grown significantly as healthcare systems focus on preventing infectious respiratory illnesses. Vaccines targeting diseases such as influenza, pneumonia, and other respiratory infections play an essential role in protecting public health. Increasing vaccination programs and awareness about disease prevention have contributed to market expansion.

Several factors are driving the growth of the respiratory disease vaccine market. Rising cases of respiratory infections and increased government investment in immunization programs have boosted vaccine demand. Additionally, advancements in vaccine research and biotechnology have led to the development of more effective and broader protection vaccines.

Looking ahead, the respiratory disease vaccine market is expected to continue expanding as healthcare organizations prioritize disease prevention strategies. Advances in vaccine technologies, including improved formulations and delivery systems, may enhance immunization effectiveness. Furthermore, global vaccination initiatives and improved healthcare access will likely support long-term market development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

  • Viral Vector
  • MRNA
  • Conjugate
  • Live Attenuated
  • Inactivated
  • Recombinant
  • Other Technologies

By Age Group

  • Pediatric
  • Adult

By Infection

  • Covid-19
  • Influenza
  • Respiratory Syncytial Virus (RSV)
  • Pneumonia
  • Other Infections

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

COMPANIES PROFILED

  • AstraZeneca, Emergent BioSolutions Inc, GSK plc, Johnson Johnson Services Inc, Merck Co Inc, Novavax, Pfizer Inc, Sanofi SA, Serum Institute of India Pvt Ltd, Sinovac
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: BY TECHNOLOGY 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Technology
  • 4.2. Viral Vector Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. MRNA Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Conjugate Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.5. Live Attenuated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.6. Inactivated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.7. Recombinant Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.8. Other Technologies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Age Group
  • 5.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: BY INFECTION 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast Infection
  • 6.2. Covid-19 Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.4. Respiratory Syncytial Virus (RSV) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.5. Pneumonia Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.6. Other Infections Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.4. Other Distribution Channels Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 8.2.1 By Technology
    • 8.2.2 By Age Group
    • 8.2.3 By Infection
    • 8.2.4 By Distribution Channel
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 8.3.1 By Technology
    • 8.3.2 By Age Group
    • 8.3.3 By Infection
    • 8.3.4 By Distribution Channel
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 8.4.1 By Technology
    • 8.4.2 By Age Group
    • 8.4.3 By Infection
    • 8.4.4 By Distribution Channel
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 8.5.1 By Technology
    • 8.5.2 By Age Group
    • 8.5.3 By Infection
    • 8.5.4 By Distribution Channel
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 8.6.1 By Technology
    • 8.6.2 By Age Group
    • 8.6.3 By Infection
    • 8.6.4 By Distribution Channel
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL RESPIRATORY DISEASE VACCINE INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 AstraZeneca
    • 10.2.2 Emergent BioSolutions Inc
    • 10.2.3 GSK Plc
    • 10.2.4 Johnson & Johnson Services Inc
    • 10.2.5 Merck & Co. Inc
    • 10.2.6 Novavax
    • 10.2.7 Pfizer Inc
    • 10.2.8 Sanofi SA
    • 10.2.9 Serum Institute Of India Pvt. Ltd
    • 10.2.10 Sinovac